Odds of hep C recurrence ‘low’ after achieving SVR, even in high-risk groups
Patients treated with direct-acting antivirals are more likely to acquire a new infection than relapse, data show
Patients with hepatitis C who have achieved a sustained virological response after direct-acting antiviral (DAA) therapy are unlikely to develop the disease again, even with high-risk behaviours, a literature review finds.
The findings suggest doctors should not be reluctant to prescribe DAA therapy for people who remain injecting drug users, are in prison, or are men who have sex with men, the researchers say.
